Quell Therapeutics and an emerging area of cell therapy

Syncona interview
Published 15 Oct 2019

Inside Syncona: Alberto Sanchez-Fueyo

Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.

Quell Therapeutics is one of Syncona’s ‘Third Wave’ cell therapy portfolio companies. It was founded in March 2019 with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of conditions such as solid organ transplant rejection, autoimmune and inflammatory diseases.

The business was founded by Syncona in partnership with six leading experts in the Treg field. Alberto, one of the founders, is a Professor of Hepatology at Kings College London and is an expert in liver transplantation.

“This is the type of platform that we have established at Quell Therapeutics with the vision of treating inflammatory disorders, autoimmune diseases, and preventing rejection after transplantation.”

Alberto Sanchez-Fueyo Professor of Hepatology, Kings College London